Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joel N Buxbaum

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Trends in Biochemical Sciences|November 11, 2003
Diseases of protein conformation: what do in vitro experiments tell us about in vivo diseases?Joel N Buxbaum
The New England Journal of Medicine|November 22, 2018
Oligonucleotide Drugs for Transthyretin AmyloidosisJoel N Buxbaum
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|August 17, 2006
VIth International Symposium on Familial Amyloidotic Polyneuropathy and other Transthyretin Disorders and the Vth International Workshop on Liver Transplantation in Familial Amyloidotic Polyneuropathy 24-26 August 2005 La Jolla, CA, USAJoel N Buxbaum
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|March 26, 2019
Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trialsJoel N Buxbaum
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 30, 2019
Unravelling Alzheimer's Disease: It's Not the Whole Story, but Aβ Still MattersJoel N Buxbaum
Current Opinion in Rheumatology|December 16, 2003
The systemic amyloidosesJoel N Buxbaum
The New England Journal of Medicine|July 5, 2018
Oligonucleotide Drugs for Transthyretin AmyloidosisJoel N Buxbaum
Neurology|January 25, 2006
Treatment and prevention of the amyloidoses: can the lessons learned be applied to sporadic inclusion-body myositis?Joel N Buxbaum
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 4, 2017
Alzheimer's Disease: It's More Than AβJoel N Buxbaum
Degenerative Neurological and Neuromuscular Disease|March 21, 2019
Evaluation of tafamidis as first-line therapeutic agent for transthyretin familial amyloidotic polyneuropathyJoel N Buxbaum
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Trends in Biochemical Sciences|November 11, 2003
Diseases of protein conformation: what do in vitro experiments tell us about in vivo diseases?Joel N Buxbaum
The New England Journal of Medicine|November 22, 2018
Oligonucleotide Drugs for Transthyretin AmyloidosisJoel N Buxbaum
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|August 17, 2006
VIth International Symposium on Familial Amyloidotic Polyneuropathy and other Transthyretin Disorders and the Vth International Workshop on Liver Transplantation in Familial Amyloidotic Polyneuropathy 24-26 August 2005 La Jolla, CA, USAJoel N Buxbaum
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|March 26, 2019
Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trialsJoel N Buxbaum
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 30, 2019
Unravelling Alzheimer's Disease: It's Not the Whole Story, but Aβ Still MattersJoel N Buxbaum
Current Opinion in Rheumatology|December 16, 2003
The systemic amyloidosesJoel N Buxbaum
The New England Journal of Medicine|July 5, 2018
Oligonucleotide Drugs for Transthyretin AmyloidosisJoel N Buxbaum
Neurology|January 25, 2006
Treatment and prevention of the amyloidoses: can the lessons learned be applied to sporadic inclusion-body myositis?Joel N Buxbaum
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 4, 2017
Alzheimer's Disease: It's More Than AβJoel N Buxbaum
Degenerative Neurological and Neuromuscular Disease|March 21, 2019
Evaluation of tafamidis as first-line therapeutic agent for transthyretin familial amyloidotic polyneuropathyJoel N Buxbaum
Pageof 8